Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer PatientsGrill, H. J., Ph.D.; Pollow, K., M.D.American Journal of Clinical Oncology: 1991 - Volume 14 - Issue - p 21–29 ORIGINAL ARTICLE: PDF Only Buy Abstract Author InformationAuthors Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method. From the Abteilung für Experimentelle Endokrinologie, Klinikum der Johannes Gutenberg Universität, Mainz, Germany. © Lippincott-Raven Publishers.